Research programme: cannabinoid based therapeutics - Tetra Bio Pharma

Drug Profile

Research programme: cannabinoid based therapeutics - Tetra Bio Pharma

Latest Information Update: 21 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Tetra Bio Pharma
  • Class Antineoplastics; Cannabinoids; Eye disorder therapies
  • Mechanism of Action Hedgehog protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cancer; Eye disorders

Most Recent Events

  • 19 Jul 2017 Tetra Bio Pharma enters into a Letter of Intent with Constance Therapeutics for clinical development and commercialisation of cannabinoid based therapeutics for Brain cancer in Canada
  • 19 Jul 2017 Tetra Bio Pharma and Constance Therapeutics plan a clinical trial for Brain cancer
  • 17 May 2017 Tetra BioPharma files for patent protection with US Patent and Trademark office for Cannabinoids and terpenoids combination
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top